Erythromycin Propionate in the Treatment of Staphylococcal Infection

Abstract

Get full access to this article

View all access options for this article.

References

Garrod

L. P.

(1957). The erythromycin group of antibiotics. Brit. med. J., 2, 57.

Gibson

G. L.

(1958). Erythromycin-resistant Staphylococcus pyogenes. Scot. med. J., 3, 91.

Griffith

R. S.

(1958). Laboratory and clinical studies with erythromycin propionate. Antibiot. Ann. 1958–1959, 364.

Hirsh

H. A.

Kunin

C. M.

Finland

(1959). Antibacterial activity of serum of normal men after oral doses of erythromycin propionate and triacetyloleandomycin. New Engl. J. Med., 260, 408.

Hobson

(1954). Activity of erythromycin against Staphylococcus aureus. Brit. med. J., 1, 236.

Kirby

W. H.

Maple

F. M.

O'Leary

Betty

(1953). Erythromycin serum concentrations following administration in acid resistant tablets. Antibiot. and Chemother., 3, 473.

Kunin

C. M.

Pryles

C. V.

Finland

(1958). Antibacterial activity of serum after oral dlses of Triacetyloleandomycin, Erythromycin, Potassium Penicillin V., and Penicillin V. Pediatrics, 22, 422.

Maccabe

A. F.

Gould

J. C.

(1956). The epidemiology of an erythromycin resistant staphylococcus. Scot. med. J., 1, 223.

Romansky

M. J.

Nasou

J. P.

Davis

D. S.

Rittis

R. E.

(1957). Clinical spectrum of erythromycin as evaluated in two hundred and sixty patients. J. Amer. med. Ass., 164, 1197.